Edwards Lifesciences (EW) Common Equity (2009 - 2026)

Edwards Lifesciences' Common Equity history runs 18 years deep, the most recent figure standing at $10.3 billion for Q1 2026.

• On a quarterly basis, Common Equity rose 1.33% year-over-year to $10.3 billion in Q1 2026; TTM through Mar 2026 was $10.3 billion, a 1.33% increase from a year earlier, with the FY2025 full-year figure at $10.3 billion, up 2.73% from the prior year.
• Common Equity steadied at $10.3 billion in Q1 2026 per EW's latest filing, from $10.3 billion in the prior quarter.
• Across five years, Common Equity topped out at $10.6 billion in Q2 2025 and bottomed at $5.8 billion in Q4 2022.
• The 5-year median for Common Equity is $7.2 billion (2024), against an average of $8.0 billion.
• Across the five-year window, Common Equity declined 0.5% in 2022 and surged 49.76% in 2024, its largest moves.
• Year by year, Common Equity stood at $5.8 billion in 2022, then climbed by 15.72% to $6.7 billion in 2023, then soared by 49.76% to $10.1 billion in 2024, then grew by 2.73% to $10.3 billion in 2025, then slipped by 0.1% to $10.3 billion in 2026.
• Per Business Quant, the three latest EW Common Equity figures stand at $10.3 billion (Q1 2026), $10.3 billion (Q4 2025), and $10.2 billion (Q3 2025).